PHAnews is meant to give a picture
of recent events
and activities affecting the life of the PH community.
This compilation should not be viewed as endorsement
of the information provided or its accuracy.
Medicare
Part D Presentation
This presentation addresses questions about enrollment, cost,
choosing a plan and much more. It is intended
for both medical professionals AND patients.
Pulmonary Hypertension May Indicate Hemoglobinuria: Presented at ASH
ATLANTA, GA -- December 15, 2005 -- A new study shows that pulmonary arterial hypertension (PHT) may be a common condition in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Myogen Announces Achievement of Target Enrollment for Pivotal Phase 3 ARIES-1 Trial of Ambrisentan in PAH
DENVER, Nov. 10 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced the achievement of target enrollment of 186 patients in ARIES-1, one of the Company's two pivotal Phase 3 trials of ambrisentan in patients with pulmonary arterial hypertension (PAH). A number of additional patients are in screening and the Company will allow those patients to complete the process and either be randomized into the trial or disqualified, in accordance with the trial protocol. The Company expects to report top line results of the trial in the second quarter of 2006. In addition, as previously announced, the Company expects to report top line results of ARIES-2, the other pivotal Phase 3 trial of ambrisentan in PAH, in December of this year.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information
resource for people dealing with PH -- they have ARRIVED
and are ready to ship!!!
The author, a PH patient
herself, knows what it is like to live with the disease.
She talked to many other patients, doctors, and researchers
while writing the Survival Guide. Dr. Ronald J. Oudiz
and a team of physicians with a deep knowledge of
PH edited the book for accuracy.
New edition contains
a chart of 15 drugs used to treat
PH; results of recent clinical trials;
in-depth discussion of PH secondary to other
diseases or conditions; a new chapter on
what to eat if you have PH; and much,
much more!
CoTherix and Respironics Announce Launch of New Portable Inhalation Device to Ventavis Patients
SOUTH SAN FRANCISCO, Calif. and MURRYSVILLE, Pa., Dec. 13 /PRNewswire-FirstCall/ -- CoTherix, Inc. (NASDAQ: CTRX) and Respironics, Inc. (NASDAQ: RESP) announced today the launch of a new portable, battery-operated inhalation device for the delivery of Ventavis(R) (iloprost) Inhalation Solution. The new I-neb(TM) Adaptive Aerosol Delivery(R) (AAD) device weighs less than eight ounces and can be carried discreetly in a purse, pocket or briefcase. Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH), World Health Organization Group I, in patients with New York Heart Association (NYHA) Class III or IV symptoms.
PHA
received an overwhelming number of submissions from
the PH community for our first organizational t-shirt
design contest. It was a very hard decision to make,
but we are proud to announce the winning design for
our first t-shirt.
The design was put together by Heather
Koczur. Heather has been a volunteer with PHA for
a while now, participating in our local volunteer
night, raising awareness by racing marathons, and
advocating for PH on the Hill at our congressional
lobby days, briefings and hearings. She is also active
in our message boards online and participates in her
local Northern Virginia Support Group meetings. Heather's
design was based off of a volunteer assignment she
created for our Awareness posters.
We would also like to honor Vic Cherubini's
contribution to the contest. His catchphrase from
his design, "Keep our Flame of Hope Burning Brightly"
was incorporated into her work.
We thank all participants for their
submissions.
T-shirts will be available for sale
early next year. Check back online often!
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
